"Kevetrin Pharmacokinetics Kevetrin showed a biphasic time vs. drug concentration curve with an elimination half-life of about 0.7 to 2.2 hours in mice and rats, respectively, and 1 hour in dogs and a dose dependent pattern in terms of the plasma concentration, C max, and exposure." The half-life in humans will likely approximate the half-life found in the animal studies. Half-life measures the time it takes for an administered drug to decrease its concentration in the body by 50%. This drug has short half-life - so there most likely won't be large accumulation in the body, even at mtd. There has not been evidence to support the idea that Kevetrin corrects p53 function in the long-term, only when it is active in the body. So far - it seems to be treatment specific - give it - get rid of the cancer - stop giving it. Once the MTD is established by having one patient out of 6 reach a point of dose limiting toxicity, the researchers will enroll 12 patients and administer the max tol dose to confirm if, indeed, they have reached the maximum. (maximum is when one patient out of six is made sick by the drug). Maximum tolerated dose is not the dose that will be administered long term - it is the established upper threshold of tolerability - and once it is known then work begins on comparing minimum efficacious dose threshold to MTD to find best and safest dose range.
"Kevetrin Pharmacokinetics Kevetrin showed a biphasic time
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Projected Growth in the Aluminum Beverage Can Industry
Exploring the Future of the Aluminum Beverage Can Market As the aluminum beverage can industry steers toward a monumental future, it's evident that the market has grown significantly, evolving to meet the rising demand for sustainable and practical packaging solutions. With a valuation of US$ 36.95 billion in 2024, projections indicate a remarkable increase to US$ 61.12...
Continue Reading
Artiva Biotherapeutics Welcomes Dr. Banerjee as CMO to Lead Growth
Artiva Biotherapeutics Expands Leadership Team Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a pioneering clinical-stage biotechnology firm, is excited to announce the recent appointment of Dr. Subhashis Banerjee, M.D., as the Chief Medical Officer. With an impressive history of over 20 years in clinical development specifically focused on autoimmune diseases, Dr....
Continue Reading
Texas Instruments: Unusual Options Trends Uncovered
Texas Instruments Options Insights Financial powerhouses have made a notable bullish move on Texas Instruments. Our analysis reveals intriguing trends within the options market for Texas Instruments (NASDAQ: TXN), showcasing an unusual number of trades that pinpoint shifting market sentiments. Trading Sentiment Overview Diving deeper into the data, it appears that 58% of...
Continue Reading
Bancolombia S.A. Releases Comprehensive 2024 Annual Report
Bancolombia S.A. Releases Comprehensive 2024 Annual Report Bancolombia S.A. (NYSE: CIB) has successfully filed its annual report on Form 20-F for the financial year ending December 31, 2024. This significant disclosure was made to the U.S. Securities and Exchange Commission (SEC), reflecting the company's ongoing commitment to transparency and accountability....
Continue Reading
Rising Small-Cap Stocks as Investors Eye Fed Rate Changes
Small-Cap Stocks Excelling Ahead of Interest Rate Decisions Recent patterns in the stock market reveal a notable enthusiasm for small-cap stocks, which are capturing the interest of many investors. With speculation swirling about an imminent decision from the Federal Reserve regarding interest rates, the Russell 2000 Index is experiencing impressive growth, boasting an...
Continue Reading